Esperion Therapeutics, Inc. — Director's Dealing 2013

Jun 25, 2013

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2013-06-25

Reporting Person: LANGE LOUIS G (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (186989)		Indirect
Series A Preferred Stock	$		Common Stock (14314)		Direct
Warrant to Purchase Preferred Stock	$1	2018-02-12	Series A Preferred Stock (51230)		Indirect
Stock Option (right to buy)	$1.26	2020-04-02	Common Stock (22645)		Direct
Stock Option (right to buy)	$3.70	2023-04-11	Common Stock (21471)		Direct

Footnotes

F1: The Series A Preferred Stock is convertible into Common Stock on a 6.986-for-1 basis at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F2: The reportable securities are owned directly by Asset Management Company Venture Fund, L.P. ("AMCVF"). The general partner of AMCVF is Asset Management Ventures (GP) LLC ("AMV GP"). Dr. Lange is a managing member of AMV GP, and he disclaims beneficial ownership of the shares held by AMCVF, except to the extent of his pecuniary interest therein.

F3: The warrant is immediately exercisable.

F4: Upon the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock will automatically convert on a 6.986-for-1 basis into a warrant to purchase shares of Common Stock, and the exercise price will become $6.99 per share.

F5: The Option vests in equal quarterly installments over a four-year period beginning from January 1, 2010.

F6: The Option is immediately exercisable, provided that any shares issued upon exercise will be restricted and will vest in equal monthly installments over a three-year period beginning from April 11, 2013.